The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 19, 2023

Filed:

Mar. 11, 2022
Applicant:

Shenzhen Rhegen Biotechnology Co., Ltd., Shenzhen, CN;

Inventors:

Yong Hu, Shenzhen, CN;

Miaomiao Zhang, Shenzhen, CN;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 47/64 (2017.01); A61K 47/65 (2017.01); A61K 47/54 (2017.01); A61K 48/00 (2006.01); A61P 1/16 (2006.01); C12N 15/87 (2006.01);
U.S. Cl.
CPC ...
A61K 48/0058 (2013.01); A61K 47/549 (2017.08); A61K 47/64 (2017.08); A61K 47/65 (2017.08); A61K 48/0033 (2013.01); A61P 1/16 (2018.01); C12N 15/87 (2013.01);
Abstract

Disclosed herein are an mRNA targeting molecule comprising an N-acetylgalactosamine binding polypeptide and a preparation method therefor. A plasmid vector containing a DNA fragment formed by sequentially connecting a promoter, a target gene, a specific protease cleavage sequence, and a polynucleotide sequence encoding a GBD capable of binding to N-acetylgalactosamine, is transcribed to obtain an mRNA, which is connected to a DNA-puromycin linker under the action of a T4 ligase. The resulting connection product is subjected to protein translation, followed by cleavage using a specific protease to obtain an mRNA-puromycin-GBD complex, which then binds to a GBD protein sequence under the action of an N-acetylgalactosamine transferase to form an mRNA-puromycin-GBD-GalNAc complex, thereby modifying the mRNA with GalNAc, thus achieving the purpose of precise administration in a process of mRNA drug delivery and increasing the efficacy of the mRNA drug molecule.


Find Patent Forward Citations

Loading…